Co‐administration of sertraline and haloperidol

Along with recent increased interest in the selective serotonin reuptake inhibitors, a number of studies has been undertaken to observe interactions with different drugs. When selective serotonin reuptake inhibitor was administered together with antipsychotics to schizophrenics showing depressive or obsessive symptoms and negative symptoms, meaningful results were observed. The objective of our research was to identify the changes in the concentration of plasma haloperidol when sertraline was administered to patients who already were being treated with haloperidol. Sixteen patients who did not respond to the traditional antipsychotics after 2 weeks of treatment with a certain dosage of haloperidol were administered with 50 mg of sertraline for a period of 2 weeks. The concentration changes between plasma haloperidol and the reduced haloperidol were observed using high‐powered liquid chromatography equipped with a UV detector. There was a significant increase (P< 0.01) in the concentration of haloperidol, the change being from 8.52 ± 4.22 to 10.91 ± 5.38 ng/mL. However, the change in the concentration of reduced haloperidol was from 7.41 ± 7.93 to 5.22 ± 6.10 ng/mL, showing a significant decrease. The concentrations of total plasma haloperidol showed no significant changes at all. In comparing the ratio of the reduced haloperidol and the haloperidol, the reduction ratio was down to 0.39 ± 0.27 from 0.94 ± 0.65 showing a significant decrease. There seems to be few studies done on interactions using serotonergic drugs together with antipsychotics in spite of their clinically applicable possibility. According to similar studies done in the past, co‐administering of such drugs not only increases the plasma concentration of antipsychotics, but it also results in clinical improvement of negative symptoms and aggravation of extrapyramidal symptoms. Changes in clinical symptoms and adverse effects were not observed in our study. However, we think these observations need to be included in upcoming larger scale studies.

[1]  D. Ciraulo,et al.  Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics. , 1990, Journal of clinical psychopharmacology.

[2]  B. Shaywitz,et al.  CSF neurochemistry in depressed, manic, and schizophrenic patients compared with that of normal controls. , 1984, The American journal of psychiatry.

[3]  Warrington Sj Clinical implications of the pharmacology of sertraline. , 1991 .

[4]  Iain M McIntyre,et al.  Plasma concentrations of melatonin in panic disorder. , 1990, The American journal of psychiatry.

[5]  R. Tyndale,et al.  Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase). , 1991, British journal of clinical pharmacology.

[6]  Eric R. Marsh,et al.  Fluoxetine and side effects. , 1990, Archives of general psychiatry.

[7]  S. Potkin,et al.  Low CSF 5-hydroxyindoleacetic acid in schizophrenic patients with enlarged cerebral ventricles. , 1983, The American journal of psychiatry.

[8]  R. Kahn,et al.  The role of serotonin in schizophrenia. , 1988, Schizophrenia bulletin.

[9]  M. Jann,et al.  Pharmacodynamics and pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patients , 1989, Biological Psychiatry.

[10]  Himmelhoch Jm What destroys our restraints against suicide , 1988 .

[11]  Nelson Jc Combined treatment strategies in psychiatry. , 1993 .

[12]  S. Stahl,et al.  Serotonin and schizophrenia: Correlations between serotonergic activity and schizophrenic motor behavior , 1985, Psychiatry Research.

[13]  H. Kutt,et al.  Improved liquid-chromatographic determination of haloperidol in plasma. , 1984, Clinical chemistry.

[14]  F. Goodwin,et al.  CSF 5-hydroxyindoleacetic acid levels in suicidal schizophrenic patients. , 1984, The American journal of psychiatry.

[15]  H. Meltzer,et al.  Psychopharmacology : the third generation of progress , 1987 .

[16]  J. Cummings,et al.  The neuroanatomy of depression. , 1993, The Journal of clinical psychiatry.

[17]  R J Wyatt,et al.  Increased whole blood serotonin concentrations in chronic schizophrenic patients. , 1981, Archives of general psychiatry.

[18]  D. Goff,et al.  Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenic patients. , 1990, The American journal of psychiatry.

[19]  S. Siris,et al.  Targeted treatment of depression-like symptoms in schizophrenia. , 1987, Psychopharmacology bulletin.

[20]  J. Heym,et al.  Pharmacology of sertraline: a review. , 1988, The Journal of clinical psychiatry.

[21]  V. Caillard,et al.  Sertraline: a new antidepressant. , 1988, The Journal of clinical psychiatry.

[22]  S. Siris,et al.  Use of antidepressant drugs in schizophrenia. , 1978, Archives of general psychiatry.